Ensysce Biosciences Q2 EPS $(0.22) Beats $(0.39) Estimate, Sales $181.80K Miss $300.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences (NASDAQ:ENSC) reported Q2 EPS of $(0.22), beating the $(0.39) estimate, but missed sales estimates with $181.80K against the expected $300.00K. EPS improved by 77.55% YoY, while sales decreased by 62.93% YoY.
August 14, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ensysce Biosciences reported better-than-expected Q2 EPS of $(0.22), beating the $(0.39) estimate, but missed sales estimates with $181.80K against the expected $300.00K. EPS improved significantly YoY, but sales saw a substantial decline.
The better-than-expected EPS is a positive sign, but the significant miss on sales and the YoY decline in revenue could offset the positive sentiment. Investors may have mixed reactions, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100